Research Antibodies & Reagents Market

Research Antibodies & Reagents Market by Product (Antibodies (Type, Form, Source, Research Area), Reagents), Technology (Western blot, Flow Cytometry, ELISA), Application (Proteomics, Genomics), End User (Pharma, Biotech, CROs) & Region - Global forecast to 2028

Report Code: BT 5482 Oct, 2023, by marketsandmarkets.com

The global research antibodies & reagents market in terms of revenue was estimated to be worth $11.8 billion in 2023 and is poised to reach $16.2 billion by 2028, growing at a CAGR of 6.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of the research antibodies and reagents market is largely driven by an increase in research activity—especially in the life sciences industry—along with growing industry-academia collaborations are a primary growth driver for this market. There is also an increasing emphasis on custom antibody development via CROs.

Additionally, the high growth potential in emerging economies and the rising demand for personalized therapeutics and protein requirements are expected to offer significant growth opportunities for players. On the other hand, complexities associated with antibody development and increasing pricing pressure are challenges expected to hinder market growth to a certain extent.

Research Antibodies and Reagents Market- Global Forecast to 2028

Research Antibodies and Reagents Market

To know about the assumptions considered for the study, Request for Free Sample Report

Research Antibodies and Reagents Market

Research antibodies & Reagents Market Dynamics

DRIVER: Rising funding for life science research

The R&D sector has conventionally remained capital-intensive due to long development periods and approval cycles. R&D investments occupy a prime position in global expenditure. Governments recognize R&D as a crucial aspect of a nation’s progress, international competitiveness, and public benefit. Due to this, R&D expenditure and funding have witnessed a steady increase over the years. According to CBRE Research, R&D expenditures by US life sciences companies have grown by ~ 40% over the past five years to reach nearly USD 154 billion in 2021. In the last two decades, antibodies have reformed the pharmaceutical industry landscape, and today, they are amongst the fastest-growing and most lucrative in therapeutics. As of 2022, five out of the top ten globally best-selling drugs are antibody-based, such as Humira (adalimumab), Keytruda (pembrolizumab), Stelara (ustekinumab), and Opdivo (nivolumab). The rising demand for efficient therapeutic monoclonal antibodies with fewer side effects has led to the growing focus on the R&D of biopharmaceuticals, which creates a high need for research antibodies and reagents.

RESTRAINT: Quality concerns and inadequacy of reproducible results

Variations in antibody production techniques have resulted in a lack of reproducibility of results. There are no standards for their validation nor agreed-upon definitions of reproducibility across all antibody offerings. The lot-to-lot variability of these antibodies significantly affects the results of basic research and clinical screening tests. According to an article in the Journal of Analytical Chemistry Insights, companies such as Amgen and Bayer HealthCare were unable to reproduce the most-examined landmark papers in their field. Thus, variations in the quality of antibodies are a major driver of what has been deemed a reproducibility crisis—a growing realization that the results of many biomedical experiments cannot be reproduced and that conclusions based on them may be unfounded. With the growing focus on antibody quality, research reproducibility, and technological advancements, vendors need to offer higher-quality products in the market.

OPPORTUNITY: High-growth potential of emerging economies

The Asia Pacific region has high potential and offers growth opportunities to research antibodies and reagnets market players as in forecoming period as the region has a diversified healthcare market in this region, the infectious and chronic diseases incidence rate is growing, Also, there are significant R&D fundings for genomics and proteomincs projects. The countries such as China, Brazil, & India have seen focus on proteomics projects. In these countries, proteomics research mainly focuses on the use of antibody-based proteomics involving the generation of protein-specific antibodies to functionally explore the human proteome and determine the mechanism of action of drugs. The significant growth opportunities offered by emerging countries such as China, India, and Indonesia can be attributed to the high growth in their respective pharmaceutical & biopharmaceutical sectors due to the presence of less stringent regulatory policies and low-cost and skilled labor. Owing to cost advantages and skilled labor, these countries are a hub for bioprocess outsourcing.

CHALLENGE: Complexities associated with antibody development

The development of monoclonal or polyclonal antibodies is a time-intensive and complex procedure, as it requires specific considerations such as the antigen against which antibodies need to be generated, specificity & sensitivity, and reproducibility. Besides, the technologies required for antibody production include large bioreactors, chromatography resins, filtration systems, and media and buffers for upstream processing, downstream processing, and purification. Such operations require high capital investment, making the entire procedure cost-intensive. Research antibody manufacturing can also be a time-consuming process, taking several months or even years to complete. This can be a challenge for researchers who need antibodies quickly for their research. Proper validation of antibodies is essential but can be challenging. Validating antibodies for specific applications and ensuring they target the intended protein can be time-consuming. Moreover, the average time required for the development of a particular mAb is over five months. Thus, although antibody and reagent production has seen significant advances in recent years, the requirement of high capital investments and time constraints can potentially hamper market growth to a certain extent.

Global Research antibodies & Reagents Market: Supply Chain Analysis

The research antibodies and reagents market supply chain comprise of manufacturers, distributors (involved in the supply of these products), and end customers (pharmaceutical & biotechnology companies, research laboratories, and CROs) are the key stakeholders in the supply chain of the research antibodies and reagents market. On the other hand, academic researchers, investors/funders, and health regulatory bodies are the primary influencers in this market.

Research Antibodies and Reagents Market Ecosystem

Research laboratories held a dominant share in end user segment in research antibodies & reagents industry.

Based on the end user, the global research antibodies & reagents market is categorized into research laboratories, pharmaceutical & biotechnology companies, and contract research organizations (CROs). Research laboratories segment accounted for the largest share of the market in 2022. The large share of this segment can be attributed to rising research grants, growing industry-academia collaborations for biomedical & life sciences research, and growing government funding investments for academic and research institutions.

The proteomics segment is expected to register the largest share in application segment in research antibodies & reagents industry during the forecast period.

Based on the application, the research antibodies & reagents market is segmented into proteomics, genomics, and drug development. In 2022, the proteomics segment accounted for the largest share. The large share of this segment is attributed to the high deployment of proteomics-based approaches in disease profiling, increasing government funding, rising demand for personalized and protein therapeutics, and increasing R&D expenditure.

Research Antibodies and Reagents Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America accounted for largest share in Research antibodies & reagents industry in 2022.

Geographically, the Research antibodies and reagents market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held dominant share followed by Europe. Increasing investments in the development of structure-based drug designs; growing research in genomics and proteomics; the rising demand for high-quality research tools for data reproducibility; and the focus of stakeholders on research projects involving proteins, associated biomolecules, and genes are the key factors driving the North American market.

Key players in the global research antibodies & reagents market include Abcam plc (UK), Cell Signaling Technology, Inc. (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), BD (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), Danaher (US), Lonza (Switzerland), GenScript (China), Revvity (US), SouthernBiotech (US),  Illumina, Inc. (US), ImmunoPrecise Antibodies Ltd (US), Fujirebio (Sweden), Analytik Jena GmbH+Co. KG (Germany), Omega Bio-tek, Inc. (US), Dovetail Genomics (US), Atlas Antibodies (Sweden), Rockland Immunochemicals, Inc. (US), Santa Cruz Biotechnology, Inc.(US), Jackson ImmunoResearch Inc. (US), Proteintech Group, Inc. (US), and ICL, Inc. (US).

Scope of the Research Antibodies & Reagents Industry:

Report Metric

Details

Market Revenue in 2023

$11.8 billion

Estimated Value by 2028

$16.2 billion

Revenue Rate

Poised to grow at a CAGR of 6.5%

Market Driver

Rising funding for life science research

Market Opportunity

High-growth potential of emerging economies

The study categorizes the Research Antibodies & Reagents Market to forecast revenue and analyze trends in each of the following submarkets

By Product

  • Reagent
    • Media & Sera
    • Stains & Dyes
    • Fixatives
    • Buffers
    • Solvents
    • Enzymes
    • Probes
    • Other Reagents
  • Antibodies
    • By Type
      • Primary Antibodies
      • Secondary Antibodies
    • By Form
      • Monoclonal
      • Polyclonal
      • Recombinant
    • By Source
      • Mice
      • Rabbits
      • Other Sources
    • By Research Area
      • Oncology
      • Infectious Diseases
      • Immunology
      • Neurobiology
      • Stem Cells
      • Other Research Areas

By Technology

  • Western Blotting
  • Flow Cytometry
  • Enzyme-linked immunosorbent assay (ELISA)
  • Immunohistochemistry
  • Immunofluorescence
  • Immunoprecipitation
  • Other Technologies

By Application

  • Proteomics
  • Drug Development
  • Genomics

By End User

  • Pharmaceutical & Biotechnologies Industries
  • Academic & Research Institutions
  • Contract Research Organizations

By region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • Japan
    • China
    • India
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
    • Brazil
    • RoLATAM
  • Middle East & Africa
    • Middle East
    • Africa

Recent Developments of Research Antibodies & Reagents Industry

  • In August 2023, Danaher (US) entered into a definitive agreement to acquire all the outstanding shares of Abcam plc (UK). Through this development, Abcam is expected to operate as a standalone operating company within Danaher’s Life Sciences segment.
  • In August 2023, Agilent Technologies, Inc. (US) announced the opening of a new full-scale Integrated Biology Center located at Monash University in Malaysia. The facility is focused on building local capabilities to accelerate research and development (R&D) in life science research.
  • In June 2023, Cell Signaling Technology, Inc. (US) and Lunaphore Technologies SA (Switzerland) have decided to partner to integrate CST antibodies into Lunaphore's COMET platform for Spatial Biology research.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 54)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
           1.2.2 MARKETS COVERED
                    FIGURE 1 RESEARCH ANTIBODIES AND REAGENTS MARKET
           1.2.3 YEARS CONSIDERED
    1.3 CURRENCY CONSIDERED 
    1.4 STAKEHOLDERS 
    1.5 LIMITATIONS 
    1.6 SUMMARY OF CHANGES 
           1.6.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 59)
    2.1 RESEARCH APPROACH 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS) FOR 2022
          FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS METHODOLOGY
          FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
          FIGURE 7 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2022)
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 8 MARKET VALIDATION FROM PRIMARY SOURCES
                    FIGURE 9 TOP-DOWN APPROACH
    2.3 MARKET GROWTH RATE PROJECTIONS 
          FIGURE 10 CAGR PROJECTIONS
          FIGURE 11 RESEARCH ANTIBODIES AND REAGENTS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
    2.4 DATA TRIANGULATION AND METHODOLOGY APPROACH 
          FIGURE 12 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 RECESSION IMPACT ANALYSIS 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2028 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 73)
    FIGURE 13 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 RESEARCH ANTIBODIES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 15 RESEARCH REAGENTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 16 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    FIGURE 17 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 18 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 19 GEOGRAPHIC SNAPSHOT OF RESEARCH ANTIBODIES AND REAGENTS MARKET
 
4 PREMIUM INSIGHTS (Page No. - 79)
    4.1 RESEARCH ANTIBODIES AND REAGENTS MARKET OVERVIEW 
          FIGURE 20 RISING FUNDING INVESTMENTS IN LIFE SCIENCES RESEARCH TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
    4.2 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION 
          FIGURE 21 PROTEOMICS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.3 GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 22 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
    4.4 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION 
          FIGURE 23 ASIA PACIFIC SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.5 RESEARCH ANTIBODIES AND REAGENTS MARKET: DEVELOPED VS. EMERGING MARKETS 
          FIGURE 24 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 83)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 25 RESEARCH ANTIBODIES AND REAGENTS MARKET: DRIVERS, OPPORTUNITIES, RESTRAINTS, AND CHALLENGES
          TABLE 4 RESEARCH ANTIBODIES AND REAGENTS MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Rising funding for life sciences research
                    5.2.1.2 Increasing industry-academia collaborations
                    5.2.1.3 Growing applications of biomarker identification & validation
           5.2.2 RESTRAINTS
                    5.2.2.1 Quality concerns and inadequacy of reproducible results
                    5.2.2.2 Ethical concerns for animal welfare in antibody production
           5.2.3 OPPORTUNITIES
                    5.2.3.1 High-growth potential of emerging economies
                    5.2.3.2 Personalized medicine and protein therapeutics
                    5.2.3.3 Growth in stem cell and neurobiology research
                    5.2.3.4 Outsourcing services to CROs
           5.2.4 CHALLENGES
                    5.2.4.1 Complexities associated with antibody development
                    5.2.4.2 Increasing pricing pressure
    5.3 INDUSTRY TRENDS 
           5.3.1 GROWING R&D ON THERAPEUTIC ANTIBODIES
           5.3.2 OPTIMAL USAGE OF RECOMBINANT ANTIBODIES
    5.4 SUPPLY CHAIN ANALYSIS 
          FIGURE 26 RESEARCH ANTIBODIES AND REAGENTS MARKETS: SUPPLY SIDE ANALYSIS
    5.5 PRODUCT PORTFOLIO ANALYSIS 
          TABLE 5 RESEARCH ANTIBODIES AND REAGENTS MARKET: PRODUCT PORTFOLIO ANALYSIS
    5.6 TECHNOLOGY ANALYSIS 
    5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 27 REVENUE SHIFT AND REVENUE GROWTH
    5.8 PRICING ANALYSIS 
           5.8.1 INDICATIVE PRICING ANALYSIS, BY ANTIBODIES
                    TABLE 6 INDICATIVE PRICING OF ANTIBODIES, BY KEY PLAYERS (2022)
           5.8.2 INDICATIVE PRICING ANALYSIS OF OVERALL MARKET (QUALITATIVE ANALYSIS)
    5.9 TRADE ANALYSIS (HS CODES) 
          TABLE 7 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS (HS CODE 3822), 2018–2022 (USD THOUSAND)
          TABLE 8 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS (HS CODE 3822), 2018–2022 (USD THOUSAND)
    5.10 ECOSYSTEM ANALYSIS 
           5.10.1 ROLE IN ECOSYSTEM
    5.11 PATENT ANALYSIS 
           FIGURE 28 RESEARCH ANTIBODIES AND REAGENT MARKET: PATENT ANALYSIS
           TABLE 9 INDICATIVE LIST OF PATENTS IN RESEARCH ANTIBODIES AND REAGENTS MARKET
    5.12 KEY CONFERENCES AND EVENTS 
           TABLE 10 RESEARCH ANTIBODIES AND REAGENTS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023−2024)
    5.13 REGULATORY ANALYSIS 
           5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 11 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.14 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 12 RESEARCH ANTIBODIES AND REAGENTS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.14.1 THREAT OF NEW ENTRANTS
           5.14.2 THREAT OF SUBSTITUTES
           5.14.3 BARGAINING POWER OF SUPPLIERS
           5.14.4 BARGAINING POWER OF BUYERS
           5.14.5 INTENSITY OF COMPETITIVE RIVALRY
    5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 
           FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESEARCH ANTIBODY & REAGENT PRODUCTS
           FIGURE 30 BUYING CRITERIA FOR PRODUCTS, BY END USER
 
6 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT (Page No. - 109)
    6.1 INTRODUCTION 
          TABLE 13 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 REAGENTS 
          TABLE 14 REAGENTS, BY TYPE AND APPLICATION
          TABLE 15 RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 16 RESEARCH REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 17 NORTH AMERICA: RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 18 EUROPE: RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 19 ASIA PACIFIC: RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 20 LATIN AMERICA: RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 21 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.1 MEDIA & SERA
                    6.2.1.1 Critical component in cell culture to boost demand
                                TABLE 22 RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 23 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 24 EUROPE: RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 25 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 26 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 27 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.2 STAINS & DYES
                    6.2.2.1 Growing applications in cell biology and molecular studies to fuel uptake
                                TABLE 28 RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 29 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 30 EUROPE: RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 31 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 32 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 33 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY REGION, 2021–2028 (USD MILLION)
           6.2.3 FIXATIVES
                    6.2.3.1 High utilization in immunohistochemistry and western blotting to propel market
                                TABLE 34 RESEARCH REAGENTS MARKET FOR FIXATIVES, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 35 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 36 EUROPE: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 37 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 38 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 39 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.4 BUFFERS
                    6.2.4.1 High utilization in drug development to drive market
                                TABLE 40 RESEARCH REAGENTS MARKET FOR BUFFERS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 41 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 42 EUROPE: RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 43 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 44 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 45 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.5 SOLVENTS
                    6.2.5.1 Broad applications in pharmaceutical processes and IHC assays to propel market
                                TABLE 46 RESEARCH REAGENTS MARKET FOR SOLVENTS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 47 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 48 EUROPE: RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 49 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 50 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 51 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.6 ENZYMES
                    6.2.6.1 Rising proteomic & genomic research studies to fuel uptake
                                TABLE 52 RESEARCH REAGENTS MARKET FOR ENZYMES, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 53 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 54 EUROPE: RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 55 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 56 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 57 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.7 PROBES
                    6.2.7.1 Quantitative and versatile capabilities to propel market
                                TABLE 58 RESEARCH REAGENTS MARKET FOR PROBES, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 59 NORTH AMERICA: RESEARCH REAGENTS MARKET FOR PROBES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 60 EUROPE: RESEARCH REAGENTS MARKET FOR PROBES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 61 ASIA PACIFIC: RESEARCH REAGENTS MARKET FOR PROBES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 62 LATIN AMERICA: RESEARCH REAGENTS MARKET FOR PROBES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 63 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.8 OTHER REAGENTS
                    TABLE 64 OTHER RESEARCH REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 65 NORTH AMERICA: OTHER RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 66 EUROPE: OTHER RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 67 ASIA PACIFIC: OTHER RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 68 LATIN AMERICA: OTHER RESEARCH REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 69 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET FOR OTHER RESEARCH REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 ANTIBODIES 
          TABLE 70 RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 71 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 72 EUROPE: RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 73 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 74 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 75 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.1 ANTIBODIES, BY TYPE
                    TABLE 76 ANTIBODIES, BY TYPE AND APPLICATION
                    TABLE 77 RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    6.3.1.1 Primary antibodies
                               6.3.1.1.1 Rising demand for personalized therapeutics to drive market
                                              TABLE 78 PRIMARY RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 79 NORTH AMERICA: PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 80 EUROPE: PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 81 ASIA PACIFIC: PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 82 LATIN AMERICA: PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 83 MIDDLE EAST & AFRICA: PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.1.2 Secondary antibodies
                               6.3.1.2.1 Low production costs to support market growth
                                              TABLE 84 SECONDARY RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 85 NORTH AMERICA: SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 86 EUROPE: SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 87 ASIA PACIFIC: SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 88 LATIN AMERICA: SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 89 MIDDLE EAST & AFRICA: SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.2 ANTIBODIES, BY FORM
                    TABLE 90 ANTIBODIES, BY FORM AND APPLICATION
                    TABLE 91 RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                    6.3.2.1 Monoclonal antibodies
                               6.3.2.1.1 High usage in biomedical science to boost demand
                                              TABLE 92 MONOCLONAL RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 93 NORTH AMERICA: MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 94 EUROPE: MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 95 ASIA PACIFIC: MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 96 LATIN AMERICA: MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 97 MIDDLE EAST & AFRICA: MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.2.2 Polyclonal antibodies
                               6.3.2.2.1 Ability to target specific assays to fuel uptake
                                              TABLE 98 POLYCLONAL RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 99 NORTH AMERICA: POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 100 EUROPE: POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 101 ASIA PACIFIC: POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 102 LATIN AMERICA: POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 103 MIDDLE EAST & AFRICA: POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.2.3 Recombinant antibodies
                               6.3.2.3.1 High usage in cancer treatment to fuel uptake
                                              TABLE 104 RECOMBINANT RESEARCH ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 105 NORTH AMERICA: RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 106 EUROPE: RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 107 ASIA PACIFIC: RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 108 LATIN AMERICA: RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 109 MIDDLE EAST & AFRICA: RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.3 ANTIBODIES, BY SOURCE
                    TABLE 110 ANTIBODIES, BY SOURCE AND APPLICATION
                    TABLE 111 RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                    6.3.3.1 Mice
                               6.3.3.1.1 Preferred hosts for antibody production to propel market
                                              TABLE 112 MICE ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 113 NORTH AMERICA: MICE ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 114 EUROPE: MICE ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 115 ASIA PACIFIC: MICE ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 116 LATIN AMERICA: MICE ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 117 MIDDLE EAST & AFRICA: MICE ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.3.2 Rabbits
                               6.3.3.2.1 Cost-effective benefits to drive demand
                                              TABLE 118 RABBIT ANTIBODIES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 119 NORTH AMERICA: RABBIT ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 120 EUROPE: RABBIT ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 121 ASIA PACIFIC: RABBIT ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 122 LATIN AMERICA: RABBIT ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 123 MIDDLE EAST & AFRICA: RABBIT ANTIBODIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.3.3 Other sources
                                TABLE 124 OTHER ANTIBODY SOURCES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 125 NORTH AMERICA: OTHER ANTIBODY SOURCES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 126 EUROPE: OTHER ANTIBODY SOURCES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 127 ASIA PACIFIC: OTHER ANTIBODY SOURCES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 128 LATIN AMERICA: OTHER ANTIBODY SOURCES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 129 MIDDLE EAST & AFRICA: OTHER ANTIBODY SOURCES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.4 ANTIBODIES, BY RESEARCH AREA
                    TABLE 130 ANTIBODIES, BY RESEARCH AREA AND APPLICATION
                    TABLE 131 RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                    6.3.4.1 Oncology
                               6.3.4.1.1 Rising incidence of cancer and associated oncology diagnostics to drive market
                                              TABLE 132 RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 133 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 134 EUROPE: RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 135 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 136 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 137 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.4.2 Infectious diseases
                               6.3.4.2.1 Increasing incidence of viral infections to drive market
                                              TABLE 138 RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 139 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 140 EUROPE: RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 141 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 142 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 143 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.4.3 Immunology
                               6.3.4.3.1 Growing awareness of autoimmune diseases to support market growth
                                              TABLE 144 RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 145 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 146 EUROPE: RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 147 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 148 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 149 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.4.4 Neurobiology
                               6.3.4.4.1 Wide applications in molecular & cellular neuroscience to drive market
                                              TABLE 150 RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 151 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 152 EUROPE: RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 153 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 154 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 155 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.4.5 Stem cells
                               6.3.4.5.1 Growing importance of transplantations to propel market
                                              TABLE 156 RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 157 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 158 EUROPE: RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 159 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 160 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 161 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.4.6 Other research areas
                                TABLE 162 RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 163 NORTH AMERICA: RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 164 EUROPE: RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 165 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 166 LATIN AMERICA: RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 167 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY (Page No. - 177)
    7.1 INTRODUCTION 
          TABLE 168 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    7.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
           7.2.1 ABILITY TO DETECT ONCOLOGY AND INFECTIOUS DISEASE SAMPLES TO PROPEL MARKET
                    TABLE 169 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 170 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 171 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 172 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 173 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 174 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 FLOW CYTOMETRY 
           7.3.1 GROWING APPLICATIONS IN CANCER RESEARCH TO DRIVE MARKET
                    TABLE 175 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 176 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 177 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 178 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 179 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 180 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 WESTERN BLOTTING 
           7.4.1 HIGH ACCURACY AND SIMPLIFIED ASSESSMENT TO DRIVE MARKET
                    TABLE 181 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 182 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 183 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 184 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 185 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 186 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2021–2028 (USD MILLION)
    7.5 IMMUNOFLUORESCENCE 
           7.5.1 ABILITY TO DETERMINE SPECIFIC GENE EXPRESSIONS TO SUPPORT MARKET
                    TABLE 187 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 188 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 189 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 190 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 191 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 192 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2021–2028 (USD MILLION)
    7.6 IMMUNOHISTOCHEMISTRY 
           7.6.1 GROWING APPLICATIONS IN DRUG EFFICACY TESTING TO SUPPORT MARKET GROWTH
                    TABLE 193 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 194 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 195 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 196 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 197 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 198 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021–2028 (USD MILLION)
    7.7 IMMUNOPRECIPITATION 
           7.7.1 HIGH-SPECIFICITY RESULTS TO CONTRIBUTE TO MARKET GROWTH
                    TABLE 199 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 200 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 201 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 202 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 203 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 204 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY REGION, 2021–2028 (USD MILLION)
    7.8 OTHER TECHNOLOGIES 
          TABLE 205 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
          TABLE 206 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 207 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 208 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 209 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 210 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION (Page No. - 199)
    8.1 INTRODUCTION 
          TABLE 211 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
    8.2 PROTEOMICS 
           8.2.1 RISING GOVERNMENT INVESTMENTS IN RESEARCH PROJECTS TO DRIVE MARKET
                    TABLE 212 TECHNOLOGICAL APPLICATIONS OF ANTIBODIES IN PROTEOMICS
                    TABLE 213 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 214 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 215 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 216 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 217 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 218 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 DRUG DEVELOPMENT 
           8.3.1 RISING PHARMA R&D EXPENDITURE TO PROPEL MARKET
                    FIGURE 31 APPLICATION OF ANTIBODIES IN DRUG DEVELOPMENT PROCESS
                    TABLE 219 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 220 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 221 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 222 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 223 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 224 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 GENOMICS 
           8.4.1 INCREASING INVESTMENTS IN GENOMICS MEDICINE TO SUPPORT MARKET GROWTH
                    TABLE 225 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 226 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 227 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 228 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 229 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 230 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER (Page No. - 211)
    9.1 INTRODUCTION 
          TABLE 231 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
    9.2 RESEARCH LABORATORIES 
           9.2.1 INCREASING STUDIES IN BIOMEDICAL AND LIFE SCIENCE RESEARCH TO PROPEL MARKET
                    TABLE 232 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 233 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 234 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 235 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 236 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 237 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
           9.3.1 RISING FOCUS ON DRUG DEVELOPMENT TO DRIVE MARKET
                    TABLE 238 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 239 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 240 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 241 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 242 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 243 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 CONTRACT RESEARCH ORGANIZATIONS 
           9.4.1 ASSISTED SERVICES FOR MAB DEVELOPMENT TO SUPPORT MARKET GROWTH
                    TABLE 244 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 245 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 246 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 247 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 248 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 249 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION (Page No. - 221)
     10.1 INTRODUCTION 
             TABLE 250 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 32 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET SNAPSHOT
             TABLE 251 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 252 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 253 NORTH AMERICA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 254 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 255 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
             TABLE 256 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
             TABLE 257 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
             TABLE 258 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 259 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 260 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.1 US
                        10.2.1.1 Increasing funding for oncology therapeutics to drive market
                                      TABLE 261 US NIH BUDGET FOR DISCIPLINES, FY 2019 TO FY 2022 (USD BILLION)
                                      TABLE 262 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 263 US: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 264 US: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 265 US: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                                      TABLE 266 US: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 267 US: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                                      TABLE 268 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 269 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 270 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Rising funding for biomedical research projects to drive market
                                      TABLE 271 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 272 CANADA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 273 CANADA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 274 CANADA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                                      TABLE 275 CANADA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 276 CANADA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                                      TABLE 277 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 278 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 279 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.3 NORTH AMERICA: RECESSION IMPACT
     10.3 EUROPE 
             TABLE 280 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 281 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 282 EUROPE: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 283 EUROPE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 284 EUROPE: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
             TABLE 285 EUROPE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
             TABLE 286 EUROPE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
             TABLE 287 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 288 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 289 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Growing industry-academia collaborations for life science research to drive market
                                      TABLE 290 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 291 GERMANY: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 292 GERMANY: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 293 GERMANY: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                                      TABLE 294 GERMANY: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 295 GERMANY: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                                      TABLE 296 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 297 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 298 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Rising incidence of cancer to support market growth
                                      TABLE 299 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 300 UK: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 301 UK: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 302 UK: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                                      TABLE 303 UK: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 304 UK: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                                      TABLE 305 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 306 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 307 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Rising demand for personalized therapeutics to support market growth
                                      TABLE 308 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 309 FRANCE: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 310 FRANCE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 311 FRANCE: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                                      TABLE 312 FRANCE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 313 FRANCE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                                      TABLE 314 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 315 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 316 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Federal funding for targeted research projects to support market growth
                                      TABLE 317 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 318 ITALY: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 319 ITALY: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 320 ITALY: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                                      TABLE 321 ITALY: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 322 ITALY: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                                      TABLE 323 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 324 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 325 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Favorable funding initiatives for novel therapeutic development to propel market
                                      TABLE 326 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 327 SPAIN: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 328 SPAIN: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 329 SPAIN: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                                      TABLE 330 SPAIN: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 331 SPAIN: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                                      TABLE 332 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 333 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 334 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.6 REST OF EUROPE
                        TABLE 335 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 336 REST OF EUROPE: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 337 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 338 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                        TABLE 339 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                        TABLE 340 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                        TABLE 341 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 342 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 343 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.7 EUROPE: RECESSION IMPACT
     10.4 ASIA PACIFIC 
             FIGURE 33 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET SNAPSHOT
             TABLE 344 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 345 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 346 ASIA PACIFIC: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 347 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 348 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
             TABLE 349 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
             TABLE 350 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
             TABLE 351 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 352 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 353 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.1 CHINA
                        10.4.1.1 Rising establishment of R&D facilities to propel market
                                      TABLE 354 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 355 CHINA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 356 CHINA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 357 CHINA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                                      TABLE 358 CHINA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 359 CHINA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                                      TABLE 360 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 361 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 362 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Rising growth in biotechnology industry to propel market
                                      TABLE 363 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 364 JAPAN: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 365 JAPAN: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 366 JAPAN: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                                      TABLE 367 JAPAN: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 368 JAPAN: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                                      TABLE 369 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 370 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 371 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Rising growth in pharmaceutical industry to drive market
                                      TABLE 372 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 373 INDIA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 374 INDIA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 375 INDIA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                                      TABLE 376 INDIA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 377 INDIA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                                      TABLE 378 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 379 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 380 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.4 REST OF ASIA PACIFIC
                        TABLE 381 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 382 REST OF ASIA PACIFIC: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 383 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 384 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                        TABLE 385 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                        TABLE 386 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                        TABLE 387 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 388 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 389 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.5 ASIA PACIFIC: RECESSION IMPACT
     10.5 LATIN AMERICA 
             TABLE 390 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 391 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 392 LATIN AMERICA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 393 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 394 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
             TABLE 395 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
             TABLE 396 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
             TABLE 397 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 398 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 399 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.1 BRAZIL
                        10.5.1.1 Growing hub for pharma R&D to support market growth
                                      TABLE 400 BRAZIL: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 401 BRAZIL: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 402 BRAZIL: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 403 BRAZIL: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                                      TABLE 404 BRAZIL: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 405 BRAZIL: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                                      TABLE 406 BRAZIL: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 407 BRAZIL: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 408 BRAZIL: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.2 REST OF LATIN AMERICA
                        TABLE 409 REST OF LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 410 REST OF LATIN AMERICA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 411 REST OF LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 412 REST OF LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                        TABLE 413 REST OF LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                        TABLE 414 REST OF LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                        TABLE 415 REST OF LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 416 REST OF LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 417 REST OF LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.3 LATIN AMERICA: RECESSION IMPACT
     10.6 MIDDLE EAST & AFRICA 
             TABLE 418 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 419 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 420 MIDDLE EAST & AFRICA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 421 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 422 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
             TABLE 423 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
             TABLE 424 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
             TABLE 425 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 426 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 427 MIDDLE EAST & AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.6.1 MIDDLE EAST
                        10.6.1.1 Rising research collaborations to drive market
                                      TABLE 428 MIDDLE EAST: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 429 MIDDLE EAST: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 430 MIDDLE EAST: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 431 MIDDLE EAST: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                                      TABLE 432 MIDDLE EAST: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 433 MIDDLE EAST: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                                      TABLE 434 MIDDLE EAST: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 435 MIDDLE EAST: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 436 MIDDLE EAST: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.6.2 AFRICA
                        10.6.2.1 Growing genomic studies to support market growth
                                      TABLE 437 AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 438 AFRICA: RESEARCH REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 439 AFRICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 440 AFRICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2021–2028 (USD MILLION)
                                      TABLE 441 AFRICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2021–2028 (USD MILLION)
                                      TABLE 442 AFRICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2021–2028 (USD MILLION)
                                      TABLE 443 AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 444 AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 445 AFRICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.6.3 MIDDLE EAST & AFRICA: RECESSION IMPACT
 
11 COMPETITIVE LANDSCAPE (Page No. - 313)
     11.1 OVERVIEW 
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             FIGURE 34 KEY DEVELOPMENTS IN RESEARCH ANTIBODIES AND REAGENTS MARKET
     11.3 MARKET SHARE ANALYSIS 
             11.3.1 RESEARCH ANTIBODIES AND REAGENTS MARKET: MARKET SHARE ANALYSIS
                        FIGURE 35 MARKET SHARE ANALYSIS FOR OVERALL MARKET, BY KEY PLAYER (2022)
                        TABLE 446 RESEARCH ANTIBODIES AND REAGENTS MARKET: INTENSITY OF COMPETITIVE RIVALRY
             11.3.2 RESEARCH ANTIBODIES MARKET: MARKET SHARE ANALYSIS (2022)
                        FIGURE 36 RESEARCH ANTIBODIES MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER (2022)
     11.4 REVENUE SHARE ANALYSIS OF TOP PLAYERS 
             FIGURE 37 REVENUE SHARE ANALYSIS OF TOP PLAYERS (2020–2022)
     11.5 COMPANY EVALUATION MATRIX 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 38 RESEARCH ANTIBODIES AND REAGENTS MARKET: COMPANY EVALUATION MATRIX (2022)
             11.5.5 COMPANY FOOTPRINT
                        11.5.5.1 Company footprint (25 Companies)
                                      TABLE 447 COMPANY FOOTPRINT ANALYSIS
                        11.5.5.2 Company product footprint (25 Companies)
                                      TABLE 448 PRODUCT FOOTPRINT ANALYSIS
                        11.5.5.3 Company regional footprint (25 Companies)
                                      TABLE 449 REGIONAL FOOTPRINT ANALYSIS
     11.6 START-UP/SME EVALUATION MATRIX 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 RESPONSIVE COMPANIES
             11.6.3 DYNAMIC COMPANIES
             11.6.4 STARTING BLOCKS
                        FIGURE 39 RESEARCH ANTIBODIES AND REAGENTS MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2022)
                        TABLE 450 RESEARCH ANTIBODIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
                        TABLE 451 RESEARCH ANTIBODIES AND REAGENTS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
     11.7 COMPETITIVE TRENDS 
             TABLE 452 RESEARCH ANTIBODIES AND REAGENTS MARKET: PRODUCT LAUNCHES (2020−2023)
             TABLE 453 RESEARCH ANTIBODIES AND REAGENTS MARKET: DEALS (2020−2023)
             TABLE 454 RESEARCH ANTIBODIES AND REAGENTS MARKET: OTHER DEVELOPMENTS (2020−2023)
 
12 COMPANY PROFILES (Page No. - 330)
     12.1 KEY PLAYERS 
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             12.1.1 ABCAM PLC
                        TABLE 455 ABCAM PLC: BUSINESS OVERVIEW
                        FIGURE 40 ABCAM PLC: COMPANY SNAPSHOT (2022)
             12.1.2 CELL SIGNALING TECHNOLOGY, INC.
                        TABLE 456 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
             12.1.3 THERMO FISHER SCIENTIFIC INC.
                        TABLE 457 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 41 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             12.1.4 MERCK KGAA
                        TABLE 458 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2022)
             12.1.5 BECTON, DICKINSON AND COMPANY
                        TABLE 459 BD: BUSINESS OVERVIEW
                        FIGURE 43 BD: COMPANY SNAPSHOT (2022)
             12.1.6 BIO-RAD LABORATORIES, INC.
                        TABLE 460 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 44 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
             12.1.7 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 461 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                        FIGURE 45 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
             12.1.8 AGILENT TECHNOLOGIES, INC.
                        TABLE 462 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                        FIGURE 46 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2022)
             12.1.9 DANAHER
                        TABLE 463 DANAHER: BUSINESS OVERVIEW
                        FIGURE 47 DANAHER: COMPANY SNAPSHOT (2022)
             12.1.10 LONZA GROUP
                        TABLE 464 LONZA GROUP: BUSINESS OVERVIEW
                        FIGURE 48 LONZA GROUP: COMPANY SNAPSHOT (2022)
             12.1.11 GENSCRIPT
                        TABLE 465 GENSCRIPT: BUSINESS OVERVIEW
                        FIGURE 49 GENSCRIPT: COMPANY SNAPSHOT (2022)
             12.1.12 REVVITY
                        TABLE 466 REVVITY: BUSINESS OVERVIEW
                        FIGURE 50 PERKINELMER INC.: COMPANY SNAPSHOT (2022)
             12.1.13 ILLUMINA, INC.
                        TABLE 467 ILLUMINA, INC.: BUSINESS OVERVIEW
                        FIGURE 51 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     12.2 OTHER PLAYERS 
             12.2.1 IMMUNOPRECISE ANTIBODIES LTD.
                        TABLE 468 IMMUNOPRECISE ANTIBODIES LTD.: COMPANY OVERVIEW
             12.2.2 FUJIREBIO
                        TABLE 469 FUJIREBIO: COMPANY OVERVIEW
             12.2.3 ANALYTIK JENA GMBH+CO. KG
                        TABLE 470 ANALYTIK JENA GMBH+CO. KG: COMPANY OVERVIEW
             12.2.4 OMEGA BIO-TEK, INC.
                        TABLE 471 OMEGA BIO-TEK, INC.: COMPANY OVERVIEW
             12.2.5 DOVETAIL GENOMICS
                        TABLE 472 DOVETAIL GENOMICS: COMPANY OVERVIEW
             12.2.6 ATLAS ANTIBODIES AB
                        TABLE 473 ATLAS ANTIBODIES AB: COMPANY OVERVIEW
             12.2.7 ROCKLAND IMMUNOCHEMICALS, INC.
                        TABLE 474 ROCKLAND IMMUNOCHEMICALS, INC.: BUSINESS OVERVIEW
             12.2.8 SANTA CRUZ BIOTECHNOLOGY, INC.
                        TABLE 475 SANTA CRUZ BIOTECHNOLOGY, INC.: COMPANY OVERVIEW
             12.2.9 JACKSON IMMUNORESEARCH INC.
                        TABLE 476 JACKSON IMMUNORESEARCH INC.: COMPANY OVERVIEW
             12.2.10 PROTEINTECH GROUP, INC.
                        TABLE 477 PROTEINTECH GROUP, INC.: COMPANY OVERVIEW
             12.2.11 ICL, INC.
                        TABLE 478 ICL, INC.: COMPANY OVERVIEW
             12.2.12 SOUTHERNBIOTECH
                        TABLE 479 SOUTHERNBIOTECH: COMPANY OVERVIEW
 
13 APPENDIX (Page No. - 396)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the use of widespread secondary sources; directories; databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers; annual reports; and companies’ house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of the global research antibodies and reagents market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, key developments related to market, and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the global research antibodies and reagents market. The primary sources from the demand side included industry experts, such as life science researchers.

A breakdown of the primary respondents is provided below:

Research Antibodies and Reagents Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by product, technology, application, end user, and region).

Bottom-up Approach

  • The key players in the industry and market have been identified through extensive secondary research.
  • The revenues generated from the research antibodies and reagents business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Research Antibodies and Reagents Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Top-down Approach

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

Research Antibodies and Reagents Market Size, and Share

Data Triangulation

To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Antibodies are proteins that bind to specific antigens, and reagents are chemicals or other substances used in chemical reactions. Antibodies and reagents are important components in life science research for the investigation of biological processes or causes of diseases through careful experimentation, observation, laboratory work, analysis, and testing.

Stakeholders

  • Pharmaceutical and Biotechnology Companies
  • Research Laboratories
  • Life Sciences Companies
  • Academic Research Institutes
  • Government Institutes
  • Private Research Firms
  • Contract Research Organizations (CROs)
  • Venture Capitalists and Investors

Objectives of the Study

  • To define, describe, segment, and forecast the global research antibodies and reagents market based on the product, technology, application, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and industry-specific challenges)
  • To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze the market opportunities for stakeholders and provide details of the competitive landscape for market players
  • To forecast the size of the global research antibodies and reagents market in five main regions (along with countries)—North America, Europe, Asia Pacific (APAC), Latin America, and the Middle East and Africa (MEA)
  • To profile key players in the global research antibodies and reagents market and comprehensively analyze their core competencies2 and market shares
  • To track and analyze competitive developments, such as product/technology development, partnerships, mergers, acquisitions, and expansions, and the R&D activities of the leading players in the research antibodies and reagents market
  • To benchmark players within the research antibodies and reagents market using the "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Portfolio Assessment

  • Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies.

Company Information

  • Detailed analysis and profiling of additional market players (up to three).

Geographical Analysis

  • A further breakdown of the Rest of Asia Pacific research antibodies and reagents market into countries
  • A further breakdown of the Rest of European research antibodies and reagents market into countries
  • A further breakdown of the Rest of Latin American research antibodies and reagents market into countries
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 5482
Published ON
Oct, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Research Antibodies & Reagents Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback